News Releases

September 25, 2018
Neon Therapeutics to Present at Upcoming Investor Conferences in October
CAMBRIDGE, Mass. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, President and Chief Executive Officer of Neon, will present at the following upcoming
Additional Formats
August 21, 2018
Neon Therapeutics Appoints Jolie M. Siegel as General Counsel

CAMBRIDGE, Mass. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the appointment of Jolie M. Siegel as general counsel, a newly created position. Ms.

Additional Formats
June 29, 2018
Neon Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass. , June 29, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of

Additional Formats
June 26, 2018
Neon Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price
Additional Formats
May 8, 2018
Neon Therapeutics Announces First Patient Treated in Clinical Trial Evaluating Personal Cancer Vaccine NEO-PV-01 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy
Cambridge, Mass., May 8, 2018  –  Neon Therapeutics , a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with
Additional Formats
Displaying 11 - 17 of 17